Home Cart Sign in  
Chemical Structure| 2229711-68-4 Chemical Structure| 2229711-68-4

Structure of ARV-471
CAS No.: 2229711-68-4

Chemical Structure| 2229711-68-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ARV-471 is an estrogen receptor PROTAC protein degrader that effectively removes estrogen receptors in ER+ breast cancer cells. It has potential applications in breast cancer treatment research.

Synonyms: Vepdegestrant

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ARV-471

CAS No. :2229711-68-4
Formula : C45H49N5O4
M.W : 723.90
SMILES Code : O=C([C@@H](N(CC1=C2C=CC(N3CCN(CC4CCN(C5=CC=C([C@H]6[C@@H](C7=CC=CC=C7)CCC8=C6C=CC(O)=C8)C=C5)CC4)CC3)=C1)C2=O)CC9)NC9=O
Synonyms :
Vepdegestrant
MDL No. :MFCD34184413

Safety of ARV-471

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Description
Vepdegestrant (ARV-471) serves as an orally active PROTAC estrogen receptor degrader designed for breast cancer treatment. It facilitates interactions between estrogen receptor alpha and an intracellular E3 ligase complex, leading to ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant effectively degrades ER in ER-positive breast cancer cell lines, with a half-maximal degradation concentration (DC50) of approximately 2 nM [1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05732428 Breast Cancer PHASE1 COMPLETED 2024-11-01 Cancer Hospital Chinese Academ... More >>y of Medical Science, Beijing, Beijing, 100021, China|Jilin Province Tumor Hospital, Changchun, Jilin, 130000, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.38mL

0.28mL

0.14mL

6.91mL

1.38mL

0.69mL

13.81mL

2.76mL

1.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories